Celea Therapeutics is a PureTech-founded respiratory biotherapeutics company focused on deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis and related fibrotic lung diseases. It launched in 2025 as a wholly owned subsidiary of PureTech.
PureTech Health's IPF drug deupirfenidone received orphan drug designation from the FDA and European Commission. The designation provides market exclusivity and financial incentives. A phase 3 trial is expected to begin in the first half of 2026.
PureTech Health announced that deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for idiopathic pulmonary fibrosis, with a Phase 3 trial planned for the first half of 2026.
PureTech Health's deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease. Phase 2b trial results showed superior efficacy compared to existing therapies.
